Full
Outline
With the optimization of drug evaluation and approval system in China, an increasing number of “global new” innovative drugs, especially those with conditional approval, are being marketed in China. For such drugs that have not yet accumulated sufficient evidence in real world, urgent problems, such as how to balance clinical needs with the risks of medical insurance funds and scientific designing of medical insurance access plans, are yet to be solved by China medical insurance departments. While in the United Kingdom (UK), the Cancer Drugs Fund (CDF) has been set up since 2011, which specializes in compensation for anticancer drugs. Through the managed access agreements (MAAs) signed with drug manufacturers, CDF regularly collects and evaluates the real-world therapeutic data, and decides whether to include or withdraw this anticancer drug in the reimbursement scope of the National Health Service (NHS), solving the “uncertainty of drug therapeutic effect” potently. This paper analyzes the operation mode, drug types, and agreement elements of the MAAs implemented by the CDF in recent years in order to provide a reference for the medical insurance management of high-value innovative drugs reimbursement accessing in China.
42
8
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
